IgH基因重排联合Bcl-2、Ki-67鉴别B细胞淋巴瘤和增生性病变的应用研究  

The Application of IGH Gene Rearrangement in Combination with Bcl-2 and Ki-67 to Identify B Cell Lymphoma and Proliferative Lesions

作　　者：张卫东[1] Zhang Weidong(Department of Pathology,Jilin Central Hospital,Jilin Province,Jilin,Jilin,132011,China)

机构地区：[1]吉林省吉林市中心医院病理科,吉林吉林132011

出　　处：《当代医学》2018年第21期70-72,共3页Contemporary Medicine

摘　　要：目的探讨IgH基因序列重组联合Bcl-2、Ki-67作为新型生物诊断标记物的可行性。方法回顾性分析医院2016年10月~2017年10月确诊的54例弥漫性大B细胞淋巴瘤组织标本、54例增生性病变患者的组织标本及54例健康对照组,间期荧光原位杂交方法检测三组的IgH基因重排情况;免疫组织化学方法检测Bcl-2、Ki-67的表达情况,并与非恶性淋巴瘤病变进行鉴别。结果 IgH基因重排阳性率为83.33%,Bcl-2、Ki-67蛋白阳性率为62.96%、70.37%。与淋巴组织增生性患者的阳性率分别为24.07%和38.89%、33.33%,差异有统计学意义。结论 IgH基因重排联合Bcl-2、Ki-67对B细胞淋巴瘤的诊断和鉴别诊断提供了优质方法,为临床诊断提供更有利的依据。Objective To investigate the feasibility of recombinant IgH gene recombination combined with Bcl-2 and Ki-67 as novel biomarkers.Methods Retrospective analysis of 54 cases of diffuse large B-cell lymphoma confirmed by the hospital from October 2016 to January 2017 was performed.Tissue samples of 54 patients with proliferative lesions and 54 healthy controls were retrospectively analyzed.The hybridization method was used to detect IgH gene rearrangement in all three groups.The expression of Bcl-2 and Ki-67 was detected by immunohistochemistry and differentiated from non-malignant lymphoma.Results The positive rate of IGH gene rearrangement is 83.33%Bcl-2,the positive rate of Ki-67 protein is 62.96%and 70.37%.And lymphoproliferation in patients with positive rates were 24.07%and 38.89%、33.33%,and with statistical differences.Conclusion IGH gene rearrangement combined with Bcl-2,Ki-67 in B-cell lymphoma diagnosis and differential diagnosis provides a good method for clinical diagnosis to provide a more favorable basis.

关 键 词：B细胞淋巴瘤 淋巴组织增生 IgH BCL-2 KI-67 

分 类 号：R733.1[医药卫生—肿瘤]